TY - JOUR
T1 - HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment
T2 - A randomised pilot study (KaMon study)
AU - Hasson, Hamid
AU - Galli, Laura
AU - Gallotta, Giulia
AU - Neri, Valentina
AU - Blanc, Pierluigi
AU - D'annunzio, Marco
AU - Morsica, Giulia
AU - Sollima, Salvatore
AU - Merli, Marco
AU - Lazzarin, Adriano
AU - Uberti-Foppa, Caterina
PY - 2012
Y1 - 2012
N2 - The aim of this randomised, prospective, open-label, multicentre pilot clinical trial was to compare the 48-week tox-icity profile of lopinavir/ritonavir (LPV/r) monotherapy with LPV/r-based HAART (KaMon = Kaletra monotherapy) in HIV/HCV patients undergoing HCV treatment. The study involved 30 HIV/HCV co-infected patients naïve to anti-HCV therapy. One patient in each arm (6.7%) discontinued anti-HCV therapy because of adverse events. There were no significant between-group differences in terms of the proportion of patients experiencing AEs (p=0.999) or the number of grade 3-4 AEs (p=0.146). No HIV failure was observed. The safety profile of LPV/r monotherapy was similar to that of LPV/r-based HAART, thus encouraging HAART simplification in patients receiving anti-HCV treatment.
AB - The aim of this randomised, prospective, open-label, multicentre pilot clinical trial was to compare the 48-week tox-icity profile of lopinavir/ritonavir (LPV/r) monotherapy with LPV/r-based HAART (KaMon = Kaletra monotherapy) in HIV/HCV patients undergoing HCV treatment. The study involved 30 HIV/HCV co-infected patients naïve to anti-HCV therapy. One patient in each arm (6.7%) discontinued anti-HCV therapy because of adverse events. There were no significant between-group differences in terms of the proportion of patients experiencing AEs (p=0.999) or the number of grade 3-4 AEs (p=0.146). No HIV failure was observed. The safety profile of LPV/r monotherapy was similar to that of LPV/r-based HAART, thus encouraging HAART simplification in patients receiving anti-HCV treatment.
KW - Anti-HCV drugs
KW - HAART-simplification strategy
KW - LPV/r monotherapy
KW - Tolerability of HIV/HCV treatments
UR - http://www.scopus.com/inward/record.url?scp=84869184772&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84869184772&partnerID=8YFLogxK
M3 - Article
C2 - 23109014
AN - SCOPUS:84869184772
VL - 35
SP - 469
EP - 474
JO - New Microbiologica
JF - New Microbiologica
SN - 1121-7138
IS - 4
ER -